VBI Vaccines (VBI Vaccines) EBIT per Share : $-8.73 (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is VBI Vaccines EBIT per Share?

VBI Vaccines's EBIT per Share for the three months ended in Dec. 2023 was $0.09. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.73.

During the past 3 years, the average EBIT per Share Growth Rate was 16.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 26.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for VBI Vaccines's EBIT per Share or its related term are showing as below:

VBIV' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -188.4 Med: 5.55 Max: 56.5
Current: 16

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of VBI Vaccines was 56.50% per year. The lowest was -188.40% per year. And the median was 5.55% per year.

VBIV's 3-Year EBIT Growth Rate is ranked better than
66.9% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs VBIV: 16.00

VBI Vaccines's EBIT for the three months ended in Dec. 2023 was $2.05 Mil.

VBI Vaccines EBIT per Share Historical Data

The historical data trend for VBI Vaccines's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines EBIT per Share Chart

VBI Vaccines Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-13.00

-5.90

-7.61

-12.55

-5.44

VBI Vaccines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-2.24	-3.00	-4.95	-0.87	0.09

VBI Vaccines EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

VBI Vaccines's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-84.772	/	15.572
=	-5.44

VBI Vaccines's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	2.054	/	23.919
=	0.09

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.73

VBI Vaccines (NAS:VBIV) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

VBI Vaccines EBIT per Share Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

VBI Vaccines (VBI Vaccines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (NAS:VBIV) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

LO9A:Germany

Address

160 Second Street, Floor 3, Cambridge, MA, USA, 02142

Website

https://www.vbivaccines.com

VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.

Executives

Steven Gillis	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Vaughn B Himes	director	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Robert Dillman	officer: Chief Commercial Officer	C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3, CAMBRIDGE MA 02142
Nell Beattie	officer: Director, Corp Development/IR	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Linda Bain	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Damian Braga	director	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Francisco Diaz-mitoma	officer: Chief Medical Officer	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Christopher Mcnulty	officer: CFO and Head of BD	C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeff Baxter	director, officer: President and CEO	C/O VBI VACCINES INC.,, 222 THIRD STREET, STE 2241, CAMBRIDGE MA 02142
Joanne Cordeiro	director	171 SWANTON STREET, UNIT 48, WINCHESTER MA 01890
Blaine H. Mckee	director	C/O HART, 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
Tomer Kariv	director	C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003